Internationally renowned Professors David Kerr and Nick La Thangue started OCB from the laboratories of the University of Oxford in 2012. Their aim was to discover and develop biomarkers using screening platforms to advance personalised medicine within oncology, specifically colorectal cancer and its treatments.
Since then, we have built a world class development team consisting of industry professionals, leading scientists and oncologists, retaining strong links to Oxford University. Together we have developed pioneering biomarker technology products that put each individual patient at the centre of cancer treatment.
Currently, David is chairman of TranScrip Partners LLP, base4innovation Ltd and Kirkstall Limited and was previously chairman of BioAnaLab Ltd and a non-executive director of Cobra Biologics plc. Until 2005, David was CEO of Xenova Group plc, a LSE and NASDAQ listed oncology-focussed drug discovery and development company. Prior to joining Xenova, David was President of Syva Company, a medical diagnostics business based in San Jose, California. Earlier, David worked for ICI Pharmaceuticals (now AstraZeneca), during which time he oversaw the launch of Cellmark Diagnostics and its identity and forensic testing business “DNA Fingerprinting”, and, for 14 years, he worked for Boehringer Mannheim GmBH (now part of Roche) in Europe and the Far East. David is an Honorary Fellow of Brunel University, a previous member of the Emerging Enterprise Council of EuropaBio and of the Bioscience Leadership Council until 2004. David chaired the European Working Group of the Bioscience Innovation and Growth Team charged with setting out a 10 year agenda for developing the UK’s bioscience industry.
MBA (INSEAD), MA (Cantab)
Chief Executive Officer
James is also currently Chairman of Renovos, a bioscience start-up commercialising orthopaedic technology from the University of Southampton. He is also the Royal Society’s Entrepreneur in Residence at the University of Southampton and is advising the London School of Hygiene and Tropical Medicine on spin outs. He has a broad base of experience in bioscience companies. He chaired Hygea VCT, where he led the successful turnaround of Hallmarq Veterinary Imaging. He worked in the health IT sector with Oxehealth and Oxford Biosignals and also was interim CEO at Glide. While a Director of Spectris plc, he turned around their largest subsidiary in Denmark, which was the world leader in sound and vibration products and services. His earlier corporate career included international commercial roles with Zeneca agrochemicals (formerly ICI). James has an MBA from INSEAD and a degree in Natural Sciences from Cambridge. .
BSc MSc PhD MA
Chief Scientific Officer
Nick is a founder of OCB and Professor of Cancer Biology at the University of Oxford. He is a Fellow of the Royal Society of Edinburgh, a Member of the European Molecular Biology Organisation (EMBO), a Fellow of the Academy of Medical Sciences, a Fellow of the Lister Institute and Professorial Fellow at Linacre College Oxford. Nick has founded several companies, including Prolifix and Celleron Therapeutics, and more recently Oxford Cancer Biomarkers, and has considerable experience derived from the biotechnology and pharmaceutical sectors. He served as Chief Business Development Officer and Chief Scientific Officer of TopoTarget, and engineered the IPO on the Scandinavian Stock Exchange.
CBE MD DSc FRCP (Glas, Lon, Edin) FRCGP FMedSci
David is a founder of OCB and Professor of Cancer Medicine at the University of Oxford, where he has worked with colleagues to build a new Institute for Cancer Medicine and Cancer Hospital. David has an international reputation for the treatment of, and research into, cjolorectal cancer and the quality of his work has been recognised by the award of several international prizes and the first NHS Nye-Bevan award for innovation.
David has made a significant contribution to reforming the NHS as a Founding Commissioner for Health Improvement, Chair of the National Cancer Services Collaborative, instigator of the Department of Health’s networked approach to clinical cancer research and he developed a 20 year plan for the future of the NHS in Scotland, the “Kerr Report”. David was elected Fellow of the Academy of Medical Sciences in 2000, Honorary Fellow of Royal College of General Practitioners in 2007, appointed Commander of the British Empire in 2002 and was elected President of the European Society of Medical Oncology in 2010.
BK Lee Director
Mr. Lee is a Professional Investor with extensive experience in investing in biotech and technology.
He was previously involved in foreign currency trading at the Bank of New York based in Seoul.
He also served as President of Sudokwon Environment Co.
Currently Mr. Lee is CEO of Muhan Corporation, a Seoul-based environmental company, and CEO of 29 Investment Corporation, an investment company in Vietnam.
Matthew Frohn DPhil
Matthew Frohn is a partner at Longwall Venture Partners LLP. Longwall manages two funds and invests in innovative, UK based, early stage companies in the healthcare, science and engineering sectors. Matthew has a DPhil in Biochemistry from Oxford University.
Chris Towler PhD
Chris Towler holds a doctorate in Biochemistry and has worked in both academic and commercial fields. During 23 years with Glaxo and Glaxo Wellcome, he led the development of three major new medicines and held senior international positions in Project Management and Regulatory Affairs. He subsequently moved to Imperial College London where he held a number of senior roles in the university’s management team. In 2008, he moved to Oxford University to head up a newly-formed team responsible for investing university funds in its spin-out companies, a post he held for 7 years, Chris is currently a Director or Board Observer for 4 of the university’s spin-outs.
Dean Slagel has 23 years of biopharmaceutical industry and venture investing experience and an MBA from ENPC Business School, Paris. After a global marketing management position at Tillotts Pharma, he spent 10 years with Ferring in global operations and global business development management. He has led Esperante since 2004, building an investment portfolio of up to 21 companies across North America and Europe. During this period, Esperante completed two successful exits (Thiakis and Pinnacle Biologics) and an IPO (Cara). In addition to OCB, Mr Slagel is currently a Board Director of Altacor, Atox Bio, Cara Therapeutics, Canbex Therapeutics and Haemostatix.
Baeckseung Lee PhD
Baeckseung is currently Chief Technology Officer (CTO) at CancerROP focusing molecular diagnostics and MJCellBio working on cell immunotherapy including CAR-T cell therapy in Korea. Until 2018, He worked as a research scientist at Bluebirdbio, a gene therapy company in USA. He has expertise in Genome Editing and Chimeric Antigen Receptor (CAR) therapy. Also, he is a current board member of Oxford Vacmedix working on cancer vaccines in UK. He received Ph.D. from University of Texas at Austin and finished post-doctoral training at Washington University in St Louis.
Se-Young (James) Cheon
Se-Young is currently Executive Managing Director / Head of Pharm. R&D HQs at Kwangdong Pharmaceuticals where his main area of experience and responsibility is in business development, product licensing and development. He has previously held senior managerial positions at Ahn Gook Pharm, SK Chemicals (Life Science), Ilsung Pharmaceutical.
Previously Se-Young worked at Life Science Divisional Group, Santen Pharmaceutical Co. Ltd. and Chong Kun Dang Pharm. gaining useful experience in licensing and development, marketing, regulatory affairs, and operations.
He is a Registered Pharmacist having obtained a Bachelor’s degree from Chung-Ang University, Seoul and a Masters’ degree from The Graduate School of Chung-Ang University, Seoul, South Korea. In addition, he has undertaken an Advanced Healthcare Management Program (AHP) at Seoul National University Hospital/Korea Medical Doctors Association and Executive Leadership Program (HELP) with the Health Insurance Review and Assessment Service (HIRA) also in Seoul, South Korea.